[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Andreas P. Wagner, Chief Human Resources Officer at Alignment Healthcare, Inc. (ALHC), reported an insider sale. The Form 4 shows a sale of 12,032 shares of the company's common stock on 08/25/2025 at a price of $16.47 per share, leaving Mr. Wagner with 192,043 shares beneficially owned after the transaction. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan adopted on 03/11/2025.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating pre-established instructions and reducing concerns about opportunistic timing
• Clear disclosure of post-transaction beneficial ownership (192,043 shares) improving transparency

Negative

• Insider disposition of 12,032 shares could be perceived negatively by some investors despite being planned
• Form lacks context on total outstanding shares or proportionate ownership, limiting assessment of materiality

Insights

Corporate Governance Expert

TL;DR: Insider sale executed under a 10b5-1 plan; routine disclosure but notable for transparency and timing.

The filing documents a non-derivative sale of 12,032 shares by the CHRO, executed under a pre-established Rule 10b5-1 plan adopted 03/11/2025. Use of a written plan typically reduces concerns about opportunistic timing and indicates the sale followed predetermined instructions. The remaining beneficial ownership of 192,043 shares should be monitored for changes, but the form contains no other transfers, option exercises, or derivative activity.

Securities Analyst

TL;DR: The transaction is a disclosed sale under an established plan; the market impact is likely limited based on available details.

The report specifies a single reported sale at $16.47 per share on 08/25/2025 under transaction code S(1), consistent with planned disposals. No additional context on total outstanding shares or recent insider activity is provided in the filing, so material impact cannot be assessed from this Form 4 alone. The clear documentation of the 10b5-1 adoption date improves disclosure quality for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Andreas P.

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		S(1)		12,032	D	$16.47	192,043	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/11/2025

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Andreas P. Wagner	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Andreas P. Wagner (ALHC) report on the Form 4?

The Form 4 reports a sale of 12,032 shares of Alignment Healthcare common stock on 08/25/2025 at a price of $16.47 per share.

Was the sale by the ALHC insider part of a 10b5-1 plan?

Yes. The filing indicates the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on 03/11/2025.

How many ALHC shares does Andreas P. Wagner own after the reported sale?

After the reported transaction, Mr. Wagner beneficially owned 192,043 shares according to the Form 4.

What transaction code is used in the Form 4 and what does it indicate?

The Form 4 uses transaction code S(1), indicating a sale executed under a Rule 10b5-1 trading plan as disclosed in the filing.

Does the Form 4 show any derivative transactions for ALHC by this reporting person?

No. Table II for derivative securities contains no entries; only a non-derivative common stock sale is reported.